<DOC>
	<DOCNO>NCT02104648</DOCNO>
	<brief_summary>This 2 part study evaluate safety tolerability supra-therapeutic dos RO4602522 ( Part A ) ; investigate effect RO4602522 QTcF interval healthy volunteer ( Part B ) . Part A study multiple-dose , randomize , double-blind , placebo-controlled study . Participants randomize receive daily , oral dos either RO4602522 placebo ten day . Part B study multiple-dose , randomize , double-blind , double-dummy , placebo control , positive-control , parallel group study . Participants randomize receive either multiple single dos RO4602522 receive single dos moxifloxacin 11 day . Pharmacokinetic parameter assess Parts A B ; continuous ECG recording make Part B .</brief_summary>
	<brief_title>A 2-Part Study Evaluate Safety Supra-Therapeutic Doses RO4602522 Investigate Effect RO4602522 QTc Interval</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy male female subject , 18 65 year age , inclusive . For Part B : Healthy male female subject , 18 65 year age , inclusive ( female subject repeat dose tolerated Part A ) Healthy status define absence evidence clinically significant , active chronic disease follow detailed medical surgical history , complete physical examination include vital sign , 12lead ECG , hematology , blood chemistry , serology urinalysis A BMI 18 32 kg/m2 inclusive Use highly effective contraception Pregnant breastfeed woman Suspicion alcohol drug abuse positive drug screen Positive result hepatitis B ( HBsAg ) , hepatitis C ( HCV ) , HIV 1 2 History clinically significant gastrointestinal , renal , hepatic , bronchopulmonary , neurological , psychiatric , cardiovascular , endocrinological , hematological allergic disease , metabolic disorder , cancer cirrhosis Diseases medical condition capable alter absorption , metabolism elimination drug Any prescribed overthecounter medication ( include vitamin herbal remedy ) take within 2 week prior first dose within 5 time elimination halflife medication prior first dosing ( whichever longer ) Taking nutrient know modulate CYP3A activity ( e.g. , grapefruit juice ; Seville orange ) within 2 week prior administration study drug tyramine rich nutrient 48 hour prior admission study site throughout study Participation investigational drug device study within 60 day prior screen 5 time elimination halflife medication prior first dosing ( whichever longer ) Consumption nicotine and/ tobacco product within last 45 day prior Day 1 study Part B Any clinically significant cardiovascular finding history Allergy moxifloxacin quinolone antibiotic history tendon rupture quinolonetype antibiotic confirm clinically significant allergic reaction drug , multiple allergy judgment Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>